ソムリエと製薬BDの知られざる共通点とは？
日本・台湾の創薬スタートアップ5社が集結し、熱いピッチを繰り広げます。ゲストコメンテーターに世界的製薬企業の最前線で活躍する事業開発責任者（BD）を招き、本音の鋭いフィードバックを展開。「福岡・オフライン限定」ならではの白熱の舞台が幕を開けます。
そして、ワインテイスティングから製薬企業BDの目利きを学ぶ体感型企画をご用意。ピッチでのやりとりとワインテイスティングを通じて、製薬BDのピッチでのコメントの真意・意図がより解像度高く理解できるようになることでしょう。
更に台湾VCが来日し、日本企業が台湾で活用可能な資金調達の枠組みも明らかに。近年、日本から台湾に進出したことで開発・ビジネスを加速させ大型調達、IPOやM&Aを実現した創薬スタートアップの先進事例が続々と生まれており、グローバルマーケットに挑戦する上で見逃せない情報をお届けします。
スタートアップの皆様は勿論、VC等ライフサイエンスに関わる皆様にとっても刺激的で発見に満ちた3時間です。お見逃しなく！
Sommeliers and Pharma BDs: Do They Share An Intriguing Connection?
Five Japanese and Taiwanese drug discovery startups will gather and deliver passionate pitches. A business development (BD) leader from a global pharmaceutical company at the forefront will serve as a guest commentator, providing candid and sharp feedback. This off-record event promises an electrifying stage.
Experience a hands-on program where you can learn the art of discernment from a pharmaceutical BD through a wine tasting session. Through the pitches and wine tasting, you will gain a higher-resolution understanding of the true intentions and meanings behind a pharmaceutical BD’s comments during pitches.
Additionally, a Taiwanese VC will reveal funding programs available to Japanese companies in Taiwan. In recent years, drug discovery startups that have expanded from Japan to Taiwan have accelerated their development and business, achieving major funding rounds, IPOs, and M&As. We will bring you invaluable information that cannot be missed for challenging the global market.
This 3-hour event promises to be stimulating and full of discoveries not only for startups but also for VCs and anyone involved in the life sciences industry. You won’t miss it!
■開催概要 / Outline:
日時：2024 年 7 月 19 日（金） 16：00～19：00
場所：Fukuoka Growth Next 1階イベントスペース
参加費：無料
実施英語：日本語・英英語
申込：https://docs.google.com/forms/d/e/1FAIpQLSf1UJYDyZ1tjSEA7PkXdLwTanIpy5TeY1VMiqKYAQukhund4A/viewform?usp=sf_link
主催：Fukuoka Growth Next
共催：福岡地所、M&J COMPANY
※オンライン配信はありません
■タイムスケジュール / Time Schedule:
16：00 ～ 挨拶・イベント開催目的 / Opening Remarks
16：10 ～ 企業講演 / Keynote Presentation
日本および APAC における製薬会社のイノベーションに対する見解と活用法～大胆に、大規模に、または他の活用法で？
登壇者：(五十音順)
第一三共株式会社 研究開発本部 研究統括部 研究イノベーション企画部 オープンイノベーショングループ 主幹 金澤 佳人氏
武田薬品工業株式会社 センターフォーエクスターナルイノベーション 日本・APAC, R&Aヘッド 佐藤 真功氏
アステラス製薬株式会社 事業開発部長 薬学博士 塚本 一成氏
Perspectives and Approaches to Innovation in Pharmaceutical Companies in Japan and APAC: Bold, Large-scale, or Alternative Approaches?
Speakers:
Yoshito Kanazawa, Ph.D., Daiichi Sankyo Co., Ltd.
Masanori Sato, Head, Center for External Innovation Japan/APAC, R&D, Takeda Pharmaceutical Company Limited
Issei Tsukamoto, Ph.D., Senior Vice President, Head of Business Development, Astellas Pharma Inc.
16：50 ～ 日台スタートアップ5社によるピッチ・Q&A / Startup Pitch and Q&A Session
登壇企業：
Pulxion (from Taiwan） https://www.pulxion.com.tw/
Protect Animal Health Inc. (from Taiwan） http://www.protectanimalhealth.com/index.html
more to be announced soon!
※他、日本国内からは九大等の研究者によるピッチを数社予定しております。
登壇者情報は随時こちらにて更新します。
17：50 ～ 台湾 VCによる講演 / Presentation by Taiwan VC
台湾の投資の枠組みについて / Investment Programs in Taiwan
登壇者：
Johnny Yu
Founder and Chairman, CellTech Accelerator
18：10 ～ ワークショップ / Workshop
ワインテイスティングから学ぶ製薬企業の目利き～モノの見方とその真意～
Learning to Discern Like a Pharma BD: Insights from Wine Tasting
※参加者の皆様に実際に3種類のワインをテイスティング頂きます。
※未成年の方、車でお越しの方、お酒を控えている方にはノンアルコールドリンクを提供します。
18：50 ～ フリーセッション
19：00 終了
※イベントの内容・スケジュールは変更の可能性があります。
■登壇者プロフィール(五十音順) / About Speakers：
金澤 佳人 氏
第一三共株式会社 研究開発本部 研究統括部
研究イノベーション企画部 オープンイノベーショングループ 主幹
医学博士
Yoshito Kanazawa, Ph.D.
Director, Open Innovation Group, Research & Innovation Planning Department,
Research function, R&D Division
Daiichi Sankyo Co., Ltd.
Yoshito Kanazawa is involved in partnerships with various academia and venture companies in the Open Innovation Group of the Research and Development Department. He is actively advancing the incubation of internal assets by leveraging venture capital. He graduated from the School of Pharmaceutical Sciences at Tohoku University.
佐藤 真功 氏
武田薬品工業株式会社
センターフォーエクスターナルイノベーション 日本/APAC ヘッド
Masanori Sato
Head, Center for External Innovation Japan/APAC, R&D
Takeda Pharmaceutical Company Limited
Masanori has been leading CEI (Center for External Innovation) Japan/APAC at Takeda Pharmaceutical since 2021. As regional representative of CEI, a highly integrated function encompassing capabilities on search and evaluation, transactions, alliance management and venture investment, his team is tasked with building partnerships across Japan, Asia and Pacific region (except for China), with the aim of accelerating Takeda R&D through diverse and flexible partnering models. The scope of such partnerships spans Takeda’s key therapeutic areas of interest including oncology, neuroscience and gastrointestinal and inflammatory diseases, and ranges from early academic research to early-stage clinical collaborations.
Prior to joining Takeda, he served as JPAC BD Head of Sanofi for 4 years and led licensing transactions as well as search function for innovative programs/technologies across JAPAC region including Taiwan.
He embarked on his career in the pharmaceutical industry at JT Pharma where he spent 25 years, the latest role there being BD Head leading licensing transactions or alliance management with major global pharma partners. Prior to BD assignment, he led multiple pre-clinical/clinical programs originated in JT Pharma. Of them, HIV programs resulted in R&D and commercial success as a blockbuster product around the world.
Masanori is a graduate of Kyoto University in Japan where he received a Bachelor of Agriculture.
塚本 一成 氏
事業開発部長、アステラス製薬株式会社
薬学博士
Issei Tsukamoto, Ph.D.
Senior Vice President, Head of Business Development
Astellas Pharma Inc.
Issei Tsukamoto is senior vice president and global Head of Business Development (BD) at Astellas, based out of Tokyo, Japan. He has responsibility for leading the company’s full range of dealmaking and partnering activities, from start-up investments and R&D collaborations to late-stage licensing and M&As. His BD team also includes Alliance Management functions building creative and win-win partnerships with ambitious external organizations who share visions to deliver VALUE for patients.
Following 17 years at Astellas, Issei worked for five years in Takeda Pharmaceuticals Co. Ltd., largely as Head of Japan Business Development, leading a wide range of BD transactions including portfolio transformation in Japan as the PMI through the Shire acquisition. He rejoined Astellas in 2021.
He has comprehensive knowledge, experience and an extensive network in the pharmaceutical industry, holding 13+ years’ experience in corporate development, BD and alliance management plus 11 years of experience in drug discovery.
Issei received a Ph.D. in medicinal chemistry from Tohoku University, Japan.
■進行/Moderator：
瀬尾 亨 氏
株式会社Newsight Tecch Angels 代表取締役社長
Toru Jay Seo
CEO, Newsight Tech Angels
Dr. Toru Jay Seo, CEO of Lucidaim Co. Ltd., obtained his PhD in Molecular and Cellular Pathology from Wake Forest University and completed his post-doctoral training in cardiovascular and metabolic diseases at Columbia University. He joined the faculty as an assistant professor in Department of Pediatrics at Columbia University Medical Center where he performed independent academic research in the field of lipid metabolism. In 2007, he moved to pursue a R&D career in the leading industries such as GSK, MERCK, TAISHO and PFIZER where his roles came to include project leader, global scientific committee member, team lead, and later on in business development and corporate strategic planning. Being a seasoned drug hunter in major pharma, he moved to an APAC head of Search and Evaluation, Worldwide Business Development, Chief Business Office, Pfizer Inc. in 2019. After leaving the pharma industry with a vast experience in business development and R&D in 2021, he created his own drug discovery biotechs and investment farm to pursue his vision of stimulating life science community. He also assumed the roles as an external counselor, advisor of biotech ventures and VCs while being a visiting professor of Osaka University and a visiting lecturer of Waseda Business School, Waseda University. He is an author of more than 70 peer-reviewed and review articles.
